| 產品編號 | bs-0528R |
| 英文名稱 | Rabbit Anti-CD24 antibody |
| 中文名稱 | CD24抗體 |
| 別 名 | Signal transducer CD24; CD 24; CD24 antigen (small cell lung carcinoma cluster 4 antigen); CD24 antigen; CD24 molecule; CD24A; GPI linked surface mucin; Heat stable antigen; HSA; Nectadrin; Small cell lung carcinoma cluster 4 antigen; Ly-52; CD24_HUMAN. |
 |
Specific References (4) | bs-0528R has been referenced in 4 publications.
[IF=4.103] Qi Sun. et al. Denosumab alleviates intervertebral disc degeneration adjacent to lumbar fusion by inhibiting endplate osteochondral remodeling and vertebral osteoporosis in ovariectomized rats. Arthritis Res Ther. 2021 Dec;23(1):1-16 IHC ; Rat.
[IF=3.23] Khan, Mohammed I., et al. "Comparative Gene Expression Profiling of Primary and Metastatic Renal Cell Carcinoma Stem Cell-Like Cancer Cells." PLOS ONE 11.11 (2016): e0165718. IF(ICC) ; Human.
[IF=3.17] Szafarowski T et al. Assessment of cancer stem cell marker expression in primary head and neck squamous cell carcinoma shows prognostic value for aldehyde dehydrogenase (ALDH1A1). Eur J Pharmacol. 2020 Jan 15;867:172837. IHF-P ; Human.
[IF=1.56] Wang, Xuming, et al. "Characterization of sphere?forming cells with stem?like properties from the gastric cancer cell lines MKN45 and SGC7901." Molecular Medicine Reports 10.6 (2014): 2937-2941. FCM ; Human.
|
| 研究領域 | 腫瘤 細胞生物 免疫學 神經生物學 干細胞 細胞粘附分子 細胞表面分子 糖蛋白 t-淋巴細胞 b-淋巴細胞 骨髓細胞 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Human,Rat (predicted: Mouse) |
| 產品應用 | WB=1:500-2000,Flow-Cyt=1μg /test,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 8kDa |
| 檢測分子量 | 35-45 |
| 細胞定位 | 細胞膜 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human CD24 Propeptide: 60-80/80 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產品介紹 |
This gene encodes a sialoglycoprotein that is expressed on mature granulocytes and B cells and modulates growth and differentiation signals to these cells. The precursor protein is cleaved to a short 32 amino acid mature peptide which is anchored via a glycosyl phosphatidylinositol (GPI) link to the cell surface. This gene was missing from previous genome assemblies, but is properly located on chromosome 6. Non-transcribed pseudogenes have been designated on chromosomes 1, 15, 20, and Y. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2014] Function: Modulates B-cell activation responses. Signaling could be triggered by the binding of a lectin-like ligand to the CD24 carbohydrates, and transduced by the release of second messengers derived from the GPI-anchor. Promotes AG-dependent proliferation of B-cells, and prevents their terminal differentiation into antibody-forming cells. Subcellular Location: Cell membrane. Tissue Specificity: B-cells. Expressed in a number of B-cell lines including P32/SH and Namalwa. Expressed in erythroleukemia cell and small cell lung carcinoma cell lines. Also expressed on the surface of T-cells. Post-translational modifications: Extensively O-glycosylated. DISEASE: Genetic variations in CD24 are associated with susceptibility to multiple sclerosis (MS). A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheat, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease. Note=Polymorphisms in CD24 may act as a genetic modifier for susceptibility and progression of MS in some populations, perhaps by affecting the efficiency of CD24 expression on the cell surface. Similarity: Belongs to the CD24 family. SWISS: P25063 Gene ID: 100133941 Database links: Entrez Gene: 100133941 Human Entrez Gene: 12484 Mouse Omim: 600074 Human SwissProt: P25063 Human SwissProt: P24807 Mouse Unigene: 644105 Human Unigene: 721443 Human Unigene: 29742 Mouse Unigene: 6007 Rat 神經干細胞標志物 腫瘤標志物 CD24是一種低分子質量高度糖基化的黏附分子, 主要表達在造血系統. 最近研究表明, 在造血系統腫瘤和一些器官的實體瘤表面可見CD24高表達。 近幾年很多學者認為：CD24在前列腺癌、非小細胞肺癌、鼻咽癌、原發(fā)性肝細胞癌、膽管細胞癌、麥克爾細胞癌、神經源性腫瘤、胰腺癌、胃癌、結腸癌、腎細胞癌、B細胞淋巴瘤、乳腺癌等腫瘤組織中表達增強, 且和腫瘤侵襲轉移、復發(fā)和預后相關。 |
| 產品圖片 |
Sample:
Colon carcinoma (Human) lysate at 30ug;
Heart(Rat) lysates, 30ug;
Primary: Anti-CD24 (bs-0528R) at 1:200 dilution;
Secondary: HRP conjugated Goat-Anti-Rabbit IgG(bs-0295G-HRP) at 1: 3000;
Predicted band size : 8kD
Observed band size : 35kD
Blank control: A549 (blue). Primary Antibody:Rabbit Anti-CD24 antibody(bs-0528R), Dilution: 1μg in 100 μL 1X PBS containing 0.5% BSA; Isotype Control Antibody: Rabbit IgG(orange) ,used under the same conditions ); Secondary Antibody: Goat anti-rabbit IgG-PE(white blue), Dilution: 1:200 in 1 X PBS containing 0.5% BSA.
Protocol
The cells were fixed with 2% paraformaldehyde (10 min) . Primary antibody (bs-0528R, 1μg /1x10^6 cells) were incubated for 30 min on the ice, followed by 1 X PBS containing 0.5% BSA + 1 0% goat serum (15 min) to block non-specific protein-protein interactions. Then the Goat Anti-rabbit IgG/PE antibody was added into the blocking buffer mentioned above to react with the primary antibody at 1/200 dilution for 30 min on ice. Acquisition of 20,000 events was performed.
|
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
